Publicacions en què col·labora amb Antonio Rueda Domínguez (17)

2023

  1. Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 1, pp. 209-220

  2. SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2749-2758

2019

  1. Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years

    Leukemia and Lymphoma

  2. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group

    Leukemia and Lymphoma

  3. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group

    Hematological Oncology, Vol. 37, Núm. 2, pp. 143-150

  4. Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma

    PLoS ONE, Vol. 14, Núm. 2

2017

  1. Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry

    PLoS ONE, Vol. 12, Núm. 5

  2. Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group

    Cancer, Vol. 123, Núm. 19, pp. 3709-3716

2015

  1. SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 1005-1013

  2. SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 1014-1019

2014

  1. Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: A multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group

    Leukemia and Lymphoma, Vol. 55, Núm. 1, pp. 51-55

  2. High serum levels of vascular endothelial growth factor-C have a positive impact on outcome of patients with advanced diffuse large B cell lymphoma

    Leukemia and Lymphoma

  3. Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis

    Haematologica

2012

  1. Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain?

    Clinical and Translational Oncology, Vol. 14, Núm. 5, pp. 386-390

2010

  1. SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma

    Clinical and Translational Oncology, Vol. 12, Núm. 11, pp. 760-764

2008

  1. R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: A multicentre, prospective study

    Hematological Oncology, Vol. 26, Núm. 1, pp. 27-32

1995

  1. EXPERIENCIA A 10 ANOS CON QUIMIOTERAPIA Y CIRUGIA EN LA SEGUNDA LAPAROTOMIA EN CANCER DE OVARIO AVANZADO

    Medicina Clinica, Vol. 104, Núm. 5, pp. 165-169